Maybank Research: Khazanah Nasional unlikely to privatise UEM Sunrise
KUALA LUMPUR: Liquidia Technologies, which is seeking a listing in Singapore, is said to be in talks with Khazanah Nasional Bhd to sell a stake in the biopharmaceutical company, Bloomberg reports.
The news wire reported on Friday that Liquidia was seeking a valuation of US$300mil for its listing on Singapore's Catalist Market in 2017.
Recently, the Bill & Melinda Gates Foundation made a US$10mil programme-related investment (PRI) in the company to support the development and commercialisation of safer and more effective vaccines and therapeutics.
The foundation said on its website the investment followed recent announcements of the first Liquidia clinical trial of its lead seasonal flu candidate (LIQ001) and a collaborative agreement with the PATH Malaria Vaccine Initiative (MVI).
Liquidia Technologies transforms the development of new therapies by precisely engineering drug particles.
It said its proprietary “PRINT” technology solves common problems with drug delivery and efficacy.
This technology is a scalable cGMP compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration.
According to Liquidia, it is advancing product candidates from its own pipeline. These initial product candidates, LIQ861 and LIQ865, apply the PRINT technology to better drug delivery in inhaled and pain therapeutic areas, respectively. http://liquidia.com/
